Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 8,608 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Orthopaedic Fractures
Interventions: NSAID, Gabapentinoids, placebo; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 17
States / cities: Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more

Conditions: Liver Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 2,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation Therapy, Carboplatin, Metformin, Paclitaxel; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 219
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more

Conditions: Heart Failure
Interventions: HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 50 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more

Conditions: Breast Cancer
Interventions: DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 4
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Rhematoid Arthritis
Interventions: Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 60
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: Panobinostat (LBH589), 5-Azacytidine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 8
States / cities: Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: Burns
Interventions: Not listed
Lead sponsor: Avita Medical; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 22
States / cities: Mobile, Alabama • Phoenix, Arizona • San Diego, California + 18 more

Conditions: Lung Cancer
Interventions: positron emission tomography, radionuclide imaging, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Clearwater, Florida + 17 more

Conditions: Spinal Diseases
Interventions: MAVERICK™ Disc, LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 32
States / cities: Huntsville, Alabama • Daly City, California • Los Angeles, California + 29 more

Conditions: Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
Interventions: brentuximab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 29
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 24 more

Conditions: Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions: Radezolid, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more

Conditions: Deep Vein Thrombosis, DVT
Interventions: Indigo Aspiration System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 42
States / cities: La Mesa, California • Long Beach, California • Los Angeles, California + 32 more

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions: Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 29 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 163
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more

Conditions: Cognitive Impairment, Delirium
Interventions: e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment), Standard Care; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Generalized Myasthenia Gravis
Interventions: Ravulizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more

Conditions: HCC, Racial Disparities
Interventions: Liver Link; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab; Drug
Lead sponsor: Seattle Project Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions: Jelmyto (mitomycin) for pyelocalyceal solution; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 22
States / cities: Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more

Conditions: Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Interventions: Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 66 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more

Conditions: Actinic Keratosis
Interventions: Imiquimod, Zyclara®, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more

Conditions: Diabetic Neuropathy, Painful
Interventions: pregabalin (Lyrica), Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 150
States / cities: Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more

Conditions: Cytomegalovirus
Interventions: CMV Assay; Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 1 more

Search by objective public record fields.

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases

Positron Emission Tomography for Detecting Non-small Cell Lung Cancer

MAVERICK™ Total Disc Replacement- Pivotal Study

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Effect of the HCC Liver-Link Intervention

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

Clinical Performance Evaluation of DxN CMV Assay